AUTOLOGOUS HEMATOPOIETC CELL TRANSPLANTATION (HCT) FOR HODGKIN LYMPHOMA, REAL WORLD EXPERIENCE OF A SINGLE CENTER EXPERIENCE

Abstract

Objective: Hodgkin's Lymphoma (HL) during the years became a high curable hematology malignant disease. Despite high curable rates, up to 30% of patient will relapse or will be refractory to first line therapy (R/R). In this scenario, hematopoietic cell transplantation (HCT) is an important treatment modality to reverse the poor prognosis of these R/R HL patients. Hence, our goal was to evaluate the outcomes of R/R HL pts who underwent an autologous HCT. Methodology: Pts who underwent an autologous or allogeneic HCT for R/R HL at the University of Campinas, Bone Marrow Transplantation Unit of Clinical Hospital, from 1994 to 2023, had their charts revised, retrospectively. 144 procedures were performed, 121 autologous HCT, and 23 allogeneic HCT, It was analyzed 119 (95%) patients for the first autologous HCT. Descriptive analyses, Kaplan-Meier Method, Log-Rank test to compare groups and Cox Regression were applied by IBM-SPSS 24.0. Results: The median age was 27 years (9-72), 60% male. Nodular sclerosis (63%) was the most common histology. The time from diagnosis and HCT was 23 months (6-96); 44% pts had chemoresistant disease (CT_R) and 56% chemosensitive (CT_S); the OS and PFS pts with CT_R were worse and Cox Regression analyzes confirmed as worst prognosis (OS: HR 2.29, 95%CI 1.29-4.07, p=0.004), besides that for PFS the time from diagnosis and HCT (PFS: HR 0.98, 95%CI: 0.97-0.99, p=0.007) was also another factor. Conclusion: Despite the small number of enrolled pts, our data can be compared to literature regarding OS and PSF. Chemosensitivity disease at HCT was associated with better outcome, and Autologous-HCT allows for long-term survival in R/R HL.